Sarcomas

The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.

The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

Aldoxorubicin demonstrated significant benefit to progression-free survival (PFS) compared with doxorubicin in patients with first-line, metastatic, locally advanced or unresectable soft tissue sarcomas

Final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial analyzing belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS) demonstrated that the novel agent could provide benefit in this space

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared to doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas.

Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

The list of agents currently available to treat soft-tissue sarcoma is rather short, with no drugs being approved on the basis of an improvement in overall survival in approximately 20 years.

The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.

Recently reported data demonstrate that the presence of a specific mutation in PDGFRA predicts for the lack of activity for the imatinib in patients with gastrointestinal stromal tumors.

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

The phase III PICASSO 3 trial examining palifosfamide plus doxorubicin in metastatic soft tissue sarcoma has reached its goal for progression-free survival events.

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.

Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.

The FDA has approved pazopanib for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy.